In the Russian Federation issued the first license to produce cell products

Roszdravnadzor has given out the first license for the production of biomedical cell products. The recipient became one of the Russian pharmaceutical companies, said the health Ministry.

Biomedical cellular products (BMCP) is cultured human cells, these drugs are widely used in regenerative medicine.

The therapeutic properties of this product are in the process of working with biological material obtained from the patient or a donor.

So, with autologous products can be obtained BMKP used in the treatment of diseases of musculoskeletal apparatus (e.g., restoration of damages of the cartilage surface of the joint), ophthalmology (recovery of the cornea), cancer and other diseases, which can significantly reduce disability.

“Allogeneic products are widely investigated and applied in the world for the treatment of systemic diseases, such as osteoarthritis, cardiovascular disease, gastrointestinal disease and severe life-threatening conditions, such as acute myocardial infarction or acute respiratory distress syndrome, which is one of the main complications in severe COVID-19, which is especially important at the moment”, – stressed in the Ministry of health.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]